The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Coronary endothelial and microvascular function play important roles in cardiovascular disease. We aimed to evaluate the effect of ticagrelor on coronary artery function and tested the antiplatelet effect of low dose ticagrelor in East-Asian patients. Methods: Sixty-one consecutive patients with non-significant coronary disease were included in the study. Initially, patients were randomized in 1:1:1 ratio to receive drugs: ticagrelor 90 mg twice a day (bid; n = 22), ticagrelor 45 mg bid (n = 19) or clopidogrel 75 mg once a day (qd; n = 20) and then divided into two groups (ticagrelor vs clopidogrel) for evaluation of coronary artery function, and three groups for evaluation of antiplatelet function. Endothelial dysfunction was measured by coronary flow reserve (CFR), and changes in the levels of asymmetric dimethylarginine (ADMA), cluster of differentiation (CD) 40 ligand, and P-selectin. Microvascular function was evaluated as index of microvascular resistance (IMR). Platelet reactivity was assessed by VerifyNow P2Y12 assay. Results: The levels of CFR, ADMA, and CD 40 ligand were not different between the two groups. However, P-selectin was lower in the ticagrelor group compared with clopidogrel group. IMR was significantly lower in the ticagrelor group compared with clopidogrel group (median, 15.0 [interquartile range, 12.0 to 21.0] vs. 47.5 [23.0 to 67.5], p = 0.014). There was significant difference in platelet inhibition among the three groups (ticagrelor 90 mg bid vs. ticagrelor 45 mg bid vs. clopidogrel 75 mg qd; 85.57 ± 47.63 vs. 120.33 ± 51.09 vs. 256.42 ± 55.10, p < 0.001) Conclusions: It is hypothesized that ticagrelor might ameliorate the coronary microvascular function. When compared with clopidogrel, low dose ticagrelor exhibited satisfactory antiplatelet effect in the present study.
Abstract
Background/Aims: Coronary endothelial and microvascular function play important roles in cardiovascular disease. We aimed to evaluate the effect of ticagrelor on coronary artery function and tested the antiplatelet effect of low dose ticagrelor in East-Asian patients. Methods: Sixty-one consecutive patients with non-significant coronary disease were included in the study. Initially, patients were randomized in 1:1:1 ratio to receive drugs: ticagrelor 90 mg twice a day (bid; n = 22), ticagrelor 45 mg bid (n = 19) or clopidogrel 75 mg once a day (qd; n = 20) and then divided into two groups (ticagrelor vs clopidogrel) for evaluation of coronary artery function, and three groups for evaluation of antiplatelet function. Endothelial dysfunction was measured by coronary flow reserve (CFR), and changes in the levels of asymmetric dimethylarginine (ADMA), cluster of differentiation (CD) 40 ligand, and P-selectin. Microvascular function was evaluated as index of microvascular resistance (IMR). Platelet reactivity was assessed by VerifyNow P2Y12 assay. Results: The levels of CFR, ADMA, and CD 40 ligand were not different between the two groups. However, P-selectin was lower in the ticagrelor group compared with clopidogrel group. IMR was significantly lower in the ticagrelor group compared with clopidogrel group (median, 15.0 [interquartile range, 12.0 to 21.0] vs. 47.5 [23.0 to 67.5], p = 0.014). There was significant difference in platelet inhibition among the three groups (ticagrelor 90 mg bid vs. ticagrelor 45 mg bid vs. clopidogrel 75 mg qd; 85.57 ± 47.63 vs. 120.33 ± 51.09 vs. 256.42 ± 55.10, p < 0.001) Conclusions: It is hypothesized that ticagrelor might ameliorate the coronary microvascular function. When compared with clopidogrel, low dose ticagrelor exhibited satisfactory antiplatelet effect in the present study.
참고문헌 (34)
- Van Giezen JJ, "Ticagrelor binds to human P2Y(12)independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation", J Thromb Haemost, 7, pp.1556~1565 (2009)
- Wallentin L, "Ticagrelor versus clopidogrel in patients with acute coronary syndromes", N Engl J Med, 361, pp.1045~1057 (2009)
- Wittfeldt A, "Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans", J Am Coll Cardiol, 61, pp.723~727 (2013)
- Sumaya W, "Ticagrelor : effects beyond the P2Y(12)receptor", Interv Cardiol Clin, 6, pp.49~55 (2017)
- Misumida N, "Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome : systematic review and meta-analysis", Cardiovasc Revasc Med, 19, pp.689~694 (2018)
- Li J, "Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes", Int J Clin Pharmacol Ther, 54, pp.666~674 (2016)
- 이지현, "A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome", The Korean Journal of Internal Medicine, 30(5), pp.620~628 (2015), 대한내과학회[DOI]
- Stühlinger MC, "Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor", JAMA, 287, pp.1420~1426 (2002)
- Ng MK, "Invasive assessment of the coronary microcirculation : superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve", Circulation, 113, pp.2054~2061 (2006)
- van Werkum JW, "A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention", J Thromb Haemost, 4, pp.2516~2518 (2006)
- Heitzer T, "Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease : evidence for antioxidant and antiinflammatory effects", Arterioscler Thromb Vasc Biol, 26, pp.1648~1652 (2006)
- Rudolph TK, "Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris : a randomized controlled trial", Int J Cardiol, 248, pp.7~13 (2017)
- Jeong HS, "Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non-ST-segment elevation acute coronary syndrome requiring coronary stenting : a prospective, randomized, crossover trial", JACC Cardiovasc Interv, 10, pp.1646~1658 (2017)
- Husted S, "Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel", Clin Cardiol, 33, pp.206~212 (2010)
- Palmerini T, "A randomized study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg", day versus 75 mg, Thromb Res, pp.2010, 125[DOI]
- Braun OO, "Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease", Thromb Haemost, 100, pp.626~633 (2008)
- Blann AD, "The adhesion molecule P-selectin and cardiovascular disease", Eur Heart J, 24, pp.2166~2179 (2003)
- Graf D, "A soluble form of TRAP(CD40 ligand)is rapidly released after T cell activation", Eur J Immunol, 25, pp.1749~1754 (1995)
- Varo N, "Soluble CD40L : risk prediction after acute coronary syndromes", Circulation, 108, pp.1049~1052 (2003)
- Dominguez-Rodriguez A, "Soluble CD40 ligand : interleukin-10ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction", Thromb Res, 121, pp.293~299 (2007)
- O’Connor CM, "Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure", Am J Cardiol, 83, pp.1345~1349 (1999)
- Parker C 3rd, "Soluble adhesion molecules and unstable coronary artery disease", Atherosclerosis, 156, pp.417~424 (2001)
- Lee JM, "Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis", J Am Coll Cardiol, 67, pp.1158~1169 (2016)
- Schachinger V, "Prognostic impact of coronary vasodilator dysfunction on adverse longterm outcome of coronary heart disease", Circulation, 101, pp.1899~1906 (2000)
- Cohn JN, "Surrogate markers for cardiovascular disease : functional markers", Circulation, 109(25 Suppl 1), pp.IV31~IV46 (2004)
- Herrmann J, "Coronary microvascular dysfunction in the clinical setting : from mystery to reality", Eur Heart J, 33, pp.2771~2782 (2012)
- Ariotti S, "Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers : a randomized crossover study", JACC Cardiovasc Interv, 11, pp.1576~1586 (2018)
- Xue HJ, "Comparison of half-and standard-dose ticagrelor in Chinese patients with NSTE-ACS", Platelets, 27, pp.440~445 (2016)
- Liu GZ, "Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity(divide study)", Eur J Clin Pharmacol, 75, pp.1059~1068 (2019)
- Gao CZ, "Comparison of the effects of ticagrelor and clopidogrel on inflammatory factors, vascular endothelium functions and short-term prognosis in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention : a pilot study", Cell Physiol Biochem, 48, pp.385~396 (2018)
- Park SD, "Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction(CV-TIME trial)", EuroIntervention, 12, pp.e964~e971 (2016)
- Aarnoudse W, "Epicardial stenosis severity does not affect minimal microcirculatory resistance", Circulation, 110, pp.2137~2142 (2004)
- Fearon WF, "Invasive assessment of the coronary microvasculature : the index of microcirculatory resistance", Circ Cardiovasc Interv, 10, pp.e005361~ (2017)
- Murai T, "Preprocedural fractional flow reserve and microvascular resistance predict increased hyperaemic coronary flow after elective percutaneous coronary intervention", Catheter Cardiovasc Interv, 89, pp.233~242 (2017)